Highlights Soligenix, Inc.

Equities

SNGX

US8342236044

Real-time Estimate Cboe BZX Other stock markets 10:15:14 2024-09-09 am EDT			5-day change	1st Jan Change
3.760 ^USD	+0.53%		-1.57%	-69.05%

Aug. 18	Transcript : Soligenix, Inc. - Special Call
Aug. 09	Soligenix, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Soligenix, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	Aug. 09	CI
Soligenix, Inc. Announces Significant Progress in the Treatment of Cutaneous T-Cell Lymphoma with its Investigational Drug, HyBryte?	Aug. 01	CI
Top Premarket Decliners	Jul. 12	MT
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Wednesday; Traders Await Powell's Second Day of Testimony	Jul. 10	MT
Top Premarket Gainers	Jul. 10	MT
Sector Update: Health Care Stocks Mixed Late Afternoon	Jul. 09	MT
Sector Update: Health Care Stocks Rise in Afternoon Trading	Jul. 09	MT
Soligenix Shares Rally Following Positive Trial Results in Early-Stage Lymphoma	Jul. 09	MT
Soligenix, Inc. Announces an Interim Update on the Open-Label, Investigator-Initiated Study Evaluating Extended HyBryte Treatment for Up to 12 Months in Patients with Early-Stage Cutaneous T-Cell Lymphoma	Jul. 09	CI
Soligenix, Inc. Announces Positive Clinical Results from A Comparative Study Evaluating Hybryte?? Against Valchlor®? in the Treatment of Cutaneous T-Cell Lymphoma	Jun. 25	CI
Reverse Split: 1 of 16	Jun. 05	FA
Sector Update: Health Care Stocks Retreat Late Afternoon	May. 23	MT
Sector Update: Health Care Stocks Lower Thursday Afternoon	May. 23	MT
Soligenix Seeks Shareholders' Approval for Reverse Stock Split; Shares Fall	May. 23	MT
Soligenix, Inc. Announces Positive Clinical Results from HyBryte Compatibility Study in the Treatment of Cutaneous T-Cell Lymphoma	May. 16	CI
Soligenix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 10	CI
Soligenix Extends Patent Protection for Its Filovirus Vaccine Platform to the United Kingdom and South Africa	Apr. 25	CI
Sector Update: Health Care Stocks Softer Late Afternoon	Apr. 15	MT
Sector Update: Health Care Stocks Gain Monday Afternoon	Apr. 15	MT
Soligenix Shares Rise After Active Ingredient in MarVax Gets US FDA's Orphan Drug Designation	Apr. 15	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Soligenix, Inc.

Equities

SNGX

US8342236044

Highlights

Filters